Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 5/20 | 0.54 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271125 | 0.89 | TDP1 (0.62) | TDP1TSHRMAPTPTGDR2PTGDR | |
| SCHEMBL23434870 | 0.85 | PTGDR (0.55) | TDP1TSHRMAPTPTGDR2PTGDR | |
| SCHEMBL24886126 | 0.83 | PTGDR2 (0.57) | TDP1MAPTPTGDR2SMN1; SMN2 | |
| SCHEMBL12409209 | 0.82 | HPGD (0.52) | TDP1TSHRMAPTPTGDR2SMN1; SMN2 | |
| SCHEMBL3188075 | 0.81 | PTGDR2 (0.61) | TDP1TSHRMAPTPTGDR2PTGDR | |
| SCHEMBL4810585 | 0.81 | GLA (0.46) | TDP1TSHRMAPTPTGDR2SMN1; SMN2 | |
| SCHEMBL24885619 | 0.80 | PTGDR2 (0.52) | TDP1TSHRPTGDR2SMN1; SMN2 | |
| 2,4-Dichlorophenoxyacetic Acid SCHEMBL437562 | 0.80 | TDP1 (0.82) | TDP1TSHRMAPTPTGDR2SMN1; SMN2 | |
| Metaxon SCHEMBL28681554 | 0.80 | TDP1 (0.62) | TDP1TSHRMAPTPTGDR2SMN1; SMN2 | |
| 2,4-Dichlorophenoxyacetic Acid SCHEMBL29010254 | 0.80 | TDP1 (0.82) | TDP1TSHRMAPTPTGDR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| EP-2900669-B1 | HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | TDP1 2700/4885TSHR 3003/4885MAPT 3799/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | TDP1 2921/4885TSHR 3063/4885MAPT 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.